Intensity values were quality checked, and the data set was normalized using a cubic spline algorithm. A detection p value <0.05 was set as a cut-off to filter reliable genes. All array data have been deposited in NCBI's Gene

Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE32373. Class comparison analysis to identify differentially expressed genes between Treg cells activated with OX86 or isotype control was performed using the GenePattern Software (Broad Institute-MIT). Foxp3-GFP mice were subcutaneously inoculated with CT26 and intratumorally injected with OX86 or rat SCH772984 IgG. After 24 h, Treg cells were sorted from TILs according to GFP expression. Control Treg cells were sorted from spleens of Foxp3-GFP tumor-free mice. RNA was extracted according to the manufacturer’s instructions (RNeasy MICROKIT, Qiagen) and RXDX-106 cost reverse transcribed using High-Capacity® cDNA Reverse Transcription Kits (Applied Biosystem). Real-time RT-PCR was performed on 7900 HT (Applied Biosystem), using TaqMan® Fast Universal PCR masterMix (Applied Biosystem). Assays (Applied Biosystem)

and samples were normalized over HPRT1 expression. Data were analyzed using the comparative Ct method. To predict the IRF1 binding site in IL-10, VCAM-1 and Viperin promoters, we identified the genomic sequences using the web tool Gene (http://www.ncbi.nlm.nih.gov/gene). Thiamet G Analysis of promoters was performed with the software TESS, developed by the Computational Biology and Informatics Laboratory of the University of Pennsylvania (http://www.cbil.upenn.edu/cgi-bin/tess/tess). Statistical analysis was performed using Prism software (GraphPad Software). Results are expressed as mean±SEM. Statistical

analysis was performed using a two-tailed Student’s t-test. Data were considered significantly different at p<0.05 (*p<0.05, **p<0.01, ***p<0.005 by Student's t test). This study was supported by grants from the Italian Ministry of Health and Associazione Italiana Ricerca sul Cancro (AIRC). S.P. is supported by My First AIRC grant (8726). P.P. is supported by a fellowship from FIRC (Fondazione Italiana Ricerca sul Cancro). We thank Arioli Ivano for technical assistance, Gabriella Abolafio and Andrea Vecchi for cell sorting, and Loris De Cecco for gene expression analysis. We are grateful to Christopher Karp and Giorgio Trinchieri for providing BM from IL-10 GFP mice. Conflict of interest: The authors declare no financial or commercial conflict of interest. Detailed facts of importance to specialist readers are published as ”Supporting Information”. Such documents are peer-reviewed, but not copy-edited or typeset. They are made available as submitted by the authors. "
“Preclinical evidence supports targeting the C5a receptor (C5aR) in rheumatoid arthritis (RA).